Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: Cancer J. 2022 May-Jun;28(3):208–223. doi: 10.1097/PPO.0000000000000591

Figure 3.

Figure 3

The Estrogen in the Prevention of Atherosclerosis Trial (EPAT) showed a reduction in the progression of early subclinical atherosclerosis measured by carotid artery wall intima-media thickness (CIMT) in healthy asymptomatic postmenopausal women treated with estradiol replacement therapy relative to placebo (5). In contrast, the Women’s Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial (WELL-HART) showed no effect of hormone replacement therapy on serial quantitative coronary angiography used to measure late-stage atherosclerosis lesions in symptomatic women with preexisting coronary artery disease (6). MPA = medroxyprogesterone acetate